Correction of coagulopathy in warfarin associated cerebral hemorrhage

Venkatesh Aiyagari, Fernando D. Testai

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalCurrent Opinion in Critical Care
Volume15
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Cerebral Hemorrhage
Warfarin
Anticoagulants
International Normalized Ratio
Intracranial Hemorrhages
Prothrombin
Factor VIIa
Vitamin K
Randomized Controlled Trials
Safety
Therapeutics

Keywords

  • Anticoagulation
  • Intracerebral hemorrhage
  • Therapy
  • Warfarin

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Correction of coagulopathy in warfarin associated cerebral hemorrhage. / Aiyagari, Venkatesh; Testai, Fernando D.

In: Current Opinion in Critical Care, Vol. 15, No. 2, 04.2009, p. 87-92.

Research output: Contribution to journalArticle

@article{733cc534a9594848abf2e117a37fdb14,
title = "Correction of coagulopathy in warfarin associated cerebral hemorrhage",
abstract = "PURPOSE OF REVIEW: Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.",
keywords = "Anticoagulation, Intracerebral hemorrhage, Therapy, Warfarin",
author = "Venkatesh Aiyagari and Testai, {Fernando D.}",
year = "2009",
month = "4",
doi = "10.1097/MCC.0b013e3283269e4d",
language = "English (US)",
volume = "15",
pages = "87--92",
journal = "Current Opinion in Critical Care",
issn = "1070-5295",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Correction of coagulopathy in warfarin associated cerebral hemorrhage

AU - Aiyagari, Venkatesh

AU - Testai, Fernando D.

PY - 2009/4

Y1 - 2009/4

N2 - PURPOSE OF REVIEW: Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.

AB - PURPOSE OF REVIEW: Warfarin is the most commonly used oral anticoagulant. Intracranial hemorrhage is the most serious complication of anticoagulation and the anticoagulant effect of warfarin has to be urgently reversed in this situation. Traditional methods of reversal of the anticoagulant effect of warfarin involving the use of vitamin K and fresh frozen plasma are slow and relatively ineffective and there is a need for alternative treatment approaches. RECENT FINDINGS: Agents such as prothrombin complex conjugates and recombinant activated factor VII are being increasingly used to emergently correct warfarin-associated coagulopathy. Over the last decade, several small case series have suggested that these agents may lead to more rapid correction of the INR, however, improved clinical outcome is yet to be proven. A recent small prospective trial has also demonstrated the safety of a prothrombin complex conjugate and its efficacy in rapidly correcting an elevated INR in these patients. SUMMARY: There is a need for well designed randomized clinical trials aimed at evaluating the efficacy of these agents in improving the outcome of patients with anticoagulant associated intracranial hemorrhage.

KW - Anticoagulation

KW - Intracerebral hemorrhage

KW - Therapy

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=67749106294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749106294&partnerID=8YFLogxK

U2 - 10.1097/MCC.0b013e3283269e4d

DO - 10.1097/MCC.0b013e3283269e4d

M3 - Article

VL - 15

SP - 87

EP - 92

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

SN - 1070-5295

IS - 2

ER -